You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 109 No. 11, November 1991 TABLE OF CONTENTS
  Archives
  •  Online Features
  CLINICAL SCIENCES
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

PhXA34, a New Potent Ocular Hypotensive Drug

A Study on Dose-Response Relationship and on Aqueous Humor Dynamics in Healthy Volunteers

Albert Alm, MD; Jörgen Villumsen, MD

Arch Ophthalmol. 1991;109(11):1564-1568.


Abstract

• The prostaglandin analogue PhXA34 was tested in two studies in normal human eyes; 1, 3, and 10 µg of PhXA34 reduced the intraocular pressure by about 2, 3, and 4 mm Hg, respectively, 6 to 10 hours after a single topical dose. The only side effect observed was a slight conjunctival hyperemia after 10 µg of PhXA34. In a second study we determined the effect of 10 µg of PhXA34 once daily for 7 days on intraocular pressure, outflow facility, aqueous flow, blood-aqueous barrier permeability, ocular discomfort, and hyperemia. The mean intraocular pressure was below 9 mm Hg 12 hours post dose. About one third of the intraocular pressure reduction could be explained by increased outflow facility. Aqueous flow was unaffected. Treatment caused a 21% increase in aqueous fluorescence 1 hour after an oral dose of fluorescein. Mild ocular discomfort and some hyperemia were initially observed in half of the subjects, but frequency and magnitude of these side effects declined during the study.



Author Affiliations

From the Department of Ophthalmology, University Hospital, Umeå, Sweden.


Footnotes

Accepted for publication June 17, 1991.

Reprint requests to Department of Ophthalmology, University Hospital, S-901 85 Umeå, Sweden (Dr Alm).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Can NSAIDs and prostaglandin analogues be combined?
Alm
Br J Ophthalmol 2006;90:259-260.
FULL TEXT  

Tonometric Changes of Latanoprost-Induced Intraocular Pressure Reduction after Photorefractive Keratectomy
Tamburrelli et al.
IOVS 2004;45:846-850.
ABSTRACT | FULL TEXT  

Paradoxical Intraocular Pressure Elevation After Combined Therapy With Latanoprost and Bimatoprost
Herndon et al.
Arch Ophthalmol 2002;120:847-849.
FULL TEXT  

From PGF2{{alpha}}-Isopropyl Ester to Latanoprost: A Review of the Development of Xalatan The Proctor Lecture
Stjernschantz
IOVS 2001;42:1134-1145.
FULL TEXT  

Effect of Latanoprost on Regional Blood Flow and Capillary Permeability in the Monkey Eye
Stjernschantz et al.
Arch Ophthalmol 1999;117:1363-1367.
ABSTRACT | FULL TEXT  

Assessment of Ocular Hypotensive Mechanisms and Additivity of Antiglaucoma Drugs in Humans
Kaufman
Arch Ophthalmol 1999;117:673-674.
FULL TEXT  

Effect of 8-iso Prostaglandin E2 on Aqueous Humor Dynamics in Monkeys
Wang et al.
Arch Ophthalmol 1998;116:1213-1216.
ABSTRACT | FULL TEXT  

A double masked comparison of the intraocular pressure reducing effect of latanoprost 0.005% and 0.001% administered once daily in open angle glaucoma and ocular hypertension
Fristrom and Nilsson
Br J Ophthalmol 1997;81:867-870.
ABSTRACT | FULL TEXT  

Latanoprost and Physostigmine Have Mostly Additive Ocular Hypotensive Effects in Human Eyes
Linden and Alm
Arch Ophthalmol 1997;115:857-861.
ABSTRACT  

Prostaglandins and Cholinomimetics
Kaufman
Arch Ophthalmol 1997;115:911-913.
ABSTRACT  

Effects on IOP restoration and blood-aqueous barrier after long term treatment with latanoprost in open angle glaucoma and ocular hypertension
Linden et al.
Br J Ophthalmol 1997;81:370-372.
ABSTRACT | FULL TEXT  

The Effects on Aqueous Dynamics of PhXA41, a New Prostaglandin F2{alpha} Analogue, After Topical Application in Normal and Ocular Hypertensive Human Eyes
Ziai et al.
Arch Ophthalmol 1993;111:1351-1358.
ABSTRACT  

Maintained Intraocular Pressure Reduction With Once-a-Day Application of a New Prostaglandin F2{alpha} Analogue (PhXA41) An In-Hospital, Placebo-Controlled Study
Racz et al.
Arch Ophthalmol 1993;111:657-661.
ABSTRACT  

Interaction of PhXA41, a New Prostaglandin Analogue, With Pilocarpine: A Study on Patients With Elevated Intraocular Pressure
Fristrom and Nilsson
Arch Ophthalmol 1993;111:662-665.
ABSTRACT  

Intraocular Pressure Reduction With PhXA34, a New Prostaglandin Analogue, in Patients With Ocular Hypertension
Camras et al.
Arch Ophthalmol 1992;110:1733-1738.
ABSTRACT  

PhXA34-Induced Ocular Hypotension
Kaufman
Arch Ophthalmol 1992;110:1042-1042.
ABSTRACT  

PhXA34-Induced Ocular Hypotension-Reply
Alm and Villumsen
Arch Ophthalmol 1992;110:1042-1042.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1991 American Medical Association. All Rights Reserved.